Save the date 📍 BLOODPAC’s 10-Year Anniversary In-Person Summit is coming to Washington, D.C. on March 4, 2027. We’re bringing together our community to reflect on a decade of progress and continue advancing liquid biopsy—together. Plan to join us March 3–5. More details coming soon.

#ICYMI our ED, Lauren Leiman joined Believe in Progress: An #AACR Foundation Podcast as a guest, alongside Mary Royal, and hosted by Mitch Stoller. 🎧 From lived experience to advancing liquid biopsy + MRD—worth a listen: www.youtube.com/watch?v=Nb3o...

We’re pleased to welcome @zymoresearch.bsky.social as the newest member of BLOODPAC! Zymo Research develops molecular biology products and services supporting sample collection and preservation, DNA/RNA purification, epigenetics, microbiomics, and NGS research applications.

‼️We’re hiring! BLOODPAC is seeking a Program Lead, Scientific Strategy & Policy to help advance initiatives in liquid biopsy, regulatory science, health policy, and diagnostics strategy. Join us in shaping the future of cancer diagnostics. #Reimbursement #Coverage #Payers #healthpolicy

What started as a collaborative effort to bring clarity to early detection terminology is now one of the top viewed articles in @ascptclinpharm.bsky.social Clinical and Translational Science. Huge thanks to our first co-authors and the entire ED&S WG. More work on MCED standards ahead!

We’re pleased to welcome @adaptivebiotech.bsky.social as the newest member of BLOODPAC! Adaptive Biotechnologies advances immune-driven medicine through technologies that support MRD assessment in blood cancer across clinical care and biopharma research, and immune profiling for clinical research.

We’re pleased to welcome Countable Labs as the newest member of BLOODPAC. Their Countable PCR platform is designed for applications including liquid biopsy, MRD monitoring, ctDNA quantification, and rare variant detection. Learn more at countablelabs.com

🙌 Our updated paper on generic analytical validation protocols for NGS-based #ctDNA assays is published in JCO PO! Built from years of real-world use + community feedback, this Version 2.0 reflects our commitment to keeping these resources relevant. Read it here 👉 ascopubs.org/doi/10.1200/...

Our Executive Director Lauren Leiman joined Believe in Progress: An @theaacr.bsky.social Foundation Podcast (hosted by Mitch Stoller) with Mary Royal to discuss liquid biopsy—from early detection to MRD. 🎧 Listen to the full episode here: www.youtube.com/watch?v=Nb3o...

Save the date 📍 BLOODPAC’s 10-Year Anniversary In-Person Summit is coming to Washington, D.C. on March 4, 2027. We’re bringing together our community to reflect on a decade of progress and continue advancing liquid biopsy—together. Plan to join us March 3–5. More details coming soon.

Looking ahead to IQN Path Annual Meeting in May - our Executive Director will present on advancing collaboration to accelerate implementation, highlighting BLOODPAC initiatives and Global Regulatory Working Group efforts. Join us in Naples!

Our Executive Director will be traveling to Naples, Italy this May to attend IQN Path’s Annual Meeting. Her talk will highlight BLOODPAC’s mission and key initiatives, with a special focus on the Global Regulatory Working Group’s efforts.

Thank you to everyone who joined us for the @bloodpac.bsky.social community reception during the #AACR26 Annual Meeting. 🙌It was great to connect with colleagues across the liquid biopsy community and keep the conversation on early detection going. #AACR26 #LiquidBiopsy #EarlyDetection #BLOODPAC

Thank you to everyone who made BLOODPAC’s #AACR26 session a success! From our speakers to a packed room, this work matters. 🙌Special thanks to our co-chairs Christina Clarke Dur (Grail) & Bree Mitchell (Natera) and the #AACR team for all their support. #LiquidBiopsy #EarlyDetection

#AACR26 is in full swing, and BLOODPAC’s early detection session is today! Join @theaacr.bsky.social and @bloodpac.bsky.social for a discussion on one of the key challenges facing blood-based cancer early detection tests. 📅 Apr 18 | 2:30–4 PM 🔗 www.abstractsonline.com/pp8/#!/21436...

How should we interpret performance metrics for blood-based early cancer detection tests? Join the @theaacr.bsky.social and @bloodpac.bsky.social @ #AACR26 for a session on clearer frameworks and more meaningful approaches to evaluating test performance. 🔗 www.abstractsonline.com/pp8/#!/21436...

Join the @theaacr.bsky.social and @bloodpac.bsky.social at #AACR26 for 𝘾𝙤𝙣𝙩𝙚𝙭𝙩𝙪𝙖𝙡 𝘾𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 𝙞𝙣 𝙄𝙣𝙩𝙚𝙧𝙥𝙧𝙚𝙩𝙞𝙣𝙜 𝙋𝙚𝙧𝙛𝙤𝙧𝙢𝙖𝙣𝙘𝙚 𝙤𝙛 𝘽𝙡𝙤𝙤𝙙-𝘽𝙖𝙨𝙚𝙙 𝙀𝙖𝙧𝙡𝙮 𝘾𝙖𝙣𝙘𝙚𝙧 𝘿𝙚𝙩𝙚𝙘𝙩𝙞𝙤𝙣 𝙏𝙚𝙨𝙩𝙨: 𝘼 𝘽𝙇𝙊𝙊𝘿𝙋𝘼𝘾 𝙋𝙚𝙧𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚 🔗 www.abstractsonline.com/pp8/#!/21436...

Join Lauren Leiman, our ED, for an upcoming webinar with Twist Bioscience and The Scientist: Beyond the Bottleneck: Engineering Sensitive Bespoke MRD Assays 🗓 April 13 | ⏰ 3:30 PM ET Experts will discuss challenges + new approaches in tumor-informed MRD testing. 🎧 Register: bit.ly/4sQEE9r

AACR is around the corner, and BLOODPAC is bringing the early detection conversation to the stage. Join BLOODPAC at #AACR26 to discuss evolving approaches for evaluating single- and multi-cancer detection tests and the implications for clinical use. 🗓️Apr 18 | 2:30–4 PM

Our tumor-informed MRD protocols paper is featured on the JCO Precision Oncology Conversations podcast! Grateful to JCO Precision Oncology for amplifying this work and advancing the conversation around MRD. 🎧 Listen here: ascopubs.org/do/jco-po-ar...

One month since our Q1 meeting hosted by @guardanthealth.bsky.social in San Diego! Whether advancing key deliverables or exploring what’s next for BLOODPAC, the conversations were engaging, productive, and full of energy. #BLOODPAC #LiquidBiopsy

How do we evaluate performance for blood-based cancer early detection tests? Join BLOODPAC at #AACR26 for presentations + panel discussion exploring single- and multi-cancer detection test performance, real-world prevalence, and emerging standards. 🗓️Apr 18 | 2:30–4 PM

We’re bringing a stellar lineup to BLOODPAC’s early detection session at #AACR26. Hear from experts shaping how we define and interpret performance for blood-based cancer early detection tests. 📅 Apr 18 ⏰ 2:30–4 PM

BLOODPAC’s Executive Director, Lauren Leiman, will speak at the Canaccord Genuity Early Cancer Detection Day 2026 on March 24, joining a panel on advancing next-gen cancer screening adoption. This is a virtual event. Learn more here: www.canaccordgenuity.com/capital-mark...

🚨 Don’t miss this! One of our members, PreAnalytiX, is hosting a free webinar on March 26 at 1 PM ET on cfDNA methylation profiling for early cancer detection. Experts from Keck USC & QIAGEN share insights on clinical applications. Register for free! www.qiagen.com/de-us/knowle...

Blood-based cancer early detection tests are advancing quickly but how should we interpret performance data? Join BLOODPAC at #AACR26 for a session exploring single- and multi-cancer detection test performance, real-world prevalence, and implications for clinical adoption. 🗓️ Apr 18 | 2:30–4 PM

We are pleased to welcome @eortc.org as BLOODPAC’s newest member. EORTC is an international, nonprofit cancer research organization coordinating clinical and translational studies to help improve patient outcomes worldwide. #BLOODPAC #CancerResearch

And just like that, BLOODPAC’s Q1 2026 meeting is in the books. From working group milestones to big-picture strategy, the collaboration over these two days shows why this community matters. Thank you to Guardant Health for hosting us in San Diego. On to Q3! 🚀

Celebrating the publication of the “Generic Protocols for Analytical Validation of Tumor-Informed ctDNA Assays for MRD: The BLOODPAC MRD AV Working Group Consensus Recommendation” in JCO PO and now advancing tumor-agnostic protocols. Great in-person progress on the next manuscript. #BLOODPAC #MRD

Expanding our MRD work to focus on clinical utility. At this workshop, co-chairs and members refined the goals and scope for a potential new working group. Strong engagement and great momentum for this next phase. #BLOODPAC #MRD #ClinicalUtility

We’ve launched a new diffuse large B-cell lymphoma #DLBCL Working Group!🙌 The kickoff brought together members and prospective members to discuss the focus and proposal for the group. Excited to expand into this space and get started.

A “double feature” at Q1: the Accessibility Working Group is advancing two initiatives; a peer-reviewed publication on assay-specific blood collection kits and a project exploring how clinicians perceive and use liquid biopsy. Focused on improving access from collection to care.

Day 1 of our Q1 meeting featured an update from the Reimbursement Working Group on their upcoming paper addressing Financial Toxicity in precision oncology. The goal: reduce barriers to medical necessity & improve coverage pathways while maintaining quality & expanding patient access.

At our Q1 meeting, the team rolled up their sleeves to discuss key parameters for the clinical study they’re developing, from patients to analytical partners and other critical elements of the study design. These discussions are helping lay the foundation as planning moves forward.

Productive workshop from our Early Detection & Screening Working Group at the Q1 meeting! Co-chairs Tina Clarke (GRAIL) and Bree Mitchell (Natera) shared progress as the group expands into clinical validation of early detection tests and prepares for a 2026 AACR session.

Thank you to @guardanthealth.bsky.social for hosting our Q1 meeting! Darya Chudova, Guardant's CTO & BLOODPAC's Scientific co-chair welcomed members and reminded us that BLOODPAC’s mission remains the same: reducing the time it takes for liquid biopsies to impact patient care.

Great Q1 meeting for the Multi-Omics WG at @guardanthealth.bsky.social! The team refined key lexicon terms and, after strong progress this past year, is now launching two subgroups: Pre-Analytic/Lab and Data/AI. Momentum continues! #BLOODPAC #MultiOmics

Day 2 of BLOODPAC’s Q1 2026 meeting is underway in San Diego!🌊 After a strong start yesterday, we’re diving back in with our members for working group updates, thoughtful discussion, and continued collaboration to advance liquid biopsy science. Thank you again to Guardant Health for hosting us! 🫶

A highlight from the Q1 Day 1 recap: collaboration between BLOODPAC’s Data Science and Global Regulatory Working Groups to explore how our standardization efforts in the U.S. could also support progress in the EU.

During the BLOODPAC Q1 Day 1 recap, the RDE Working Group shared a new project developing Minimum Technical Data Elements (MTDEs) for saliva and buccal samples. An outstanding group of experts is helping shape and accelerate this effort. #BLOODPAC

At the Q1 Day 1 recap, the #CHIP Working Group highlighted the publication of their lexicon, a key step toward greater clarity in the field. They’re now focusing on a new paper to help disambiguate methods for CHIP identification. 👉Lexicon paper: ascpt.onlinelibrary.wiley.com/doi/10.1111/...

BLOODPAC’s Q1 2026 meeting is live in San Diego, CA! We’re excited to gather our members for meaningful collaboration and forward-looking discussions around all things liquid biopsy. Thank you to @guardanthealth.bsky.social for hosting us. Looking forward to a dynamic and productive meeting!

For new members, our quarterly meetings offer immediate value, deep insight, open collaboration, and a strong sense of community. One of the most powerful outcomes is the development of shared tools and best-practice toolkits for the LBx community. Looking forward to our Q1 2026 meeting this week 🙌

🎉 Just 7 days to go! 🎉 BLOODPAC’s first quarter meeting is right around the corner! Join us in just one week on March 4th and 5th in San Diego, California, hosted by @guardanthealth.bsky.social . We’re so excited to see everyone there!

BLOODPAC’s quarterly meetings offer a rare model for collaboration, bringing diverse stakeholders together to develop strong, shared industry recommendations. Members see real value in working collectively to reach patients faster. Looking forward to see all our members at the Q1 2026 meeting.

Welcome Norgen Biotek to the BLOODPAC community! 🎉 Norgen Biotek is a Canadian biotech company offering sample prep and research tools used in life science and molecular diagnostics. 🌍🔬Learn more at norgenbiotek.com.

🎉 The countdown continues! 🎉 Only 14 days left until BLOODPAC’s in-person first quarter meeting! Join us on March 4th and 5th in San Diego, CA, hosted by @guardanthealth.bsky.social. We’re getting closer and can't wait to see everyone there!

BLOODPAC’s quarterly meetings provide invaluable opportunities for networking and industry insight. Members, like David Merriam, value the ability to learn from peers while shaping what comes next in diagnostics. We’re looking forward to our Q1 2026 meeting.

Whether our members are an early-stage company or an established organization, BLOODPAC’s quarterly meetings offer a unique space to collaborate, learn, and help shape the future of diagnostics. Our members say it best—this community makes a difference. Excited for our Q1 2026.

We’re pleased to welcome Insightec as the newest member of BLOODPAC! Insightec is a global healthcare company advancing focused ultrasound medical technologies used in clinical practice worldwide. Learn more at insightec.com.